Evaxion Biotech A/S ADR (NASDAQ:EVAX) has a beta value of -0.09 and has seen 3.28 million shares traded in the last trading session. The company, currently valued at $7.02M, closed the last trade at $6.00 per share which meant it lost -$0.03 on the day or -0.50% during that session. The EVAX stock price is -790.83% off its 52-week high price of $53.45 and 60.33% above the 52-week low of $2.38. If we look at the company’s 10-day average daily trading volume, we find that it stood at 6.11 million shares traded. The 3-month trading volume is 1.07 million shares.

The consensus among analysts is that Evaxion Biotech A/S ADR (EVAX) is Buy stock at the moment, with a recommendation rating of 1.00. 0 analysts rate the stock as a Sell, while 0 rate it as Overweight. 0 out of 1 have rated it as a Hold, with 1 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -0.15.

Evaxion Biotech A/S ADR (NASDAQ:EVAX) trade information

Sporting -0.50% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on recent trading when the EVAX stock price touched $6.00 or saw a rise of 38.78%. Year-to-date, Evaxion Biotech A/S ADR shares have moved 41.94%, while the 5-day performance has seen it change 94.17%. Over the past 30 days, the shares of Evaxion Biotech A/S ADR (NASDAQ:EVAX) have changed 32.20%. Short interest in the company has seen 0.2 million shares shorted with days to cover at 1.07.

Evaxion Biotech A/S ADR (EVAX) estimates and forecasts

Figures show that Evaxion Biotech A/S ADR shares have outperformed across the wider relevant industry. The company’s shares have lost -58.76% over the past 6 months, with this year growth rate of 89.38%, compared to 16.40% for the industry. Revenue growth from the last financial year stood is estimated to be 0.00%.

2 analysts offering their estimates for the company have set an average revenue estimate of 1.66M for the current quarter. 1 have an estimated revenue figure of 3.2M for the next ending quarter.

If we evaluate the company’s growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was -18.88% over the past 5 years.

EVAX Dividends

Evaxion Biotech A/S ADR is expected to release its next earnings report in February this year, and investors are excited at the prospect of better dividends despite the company’s debt issue.